相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance
Rachelle Tibbetts et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Beyond Black and White: Mapping Misclassification of Medicare Beneficiaries Race and Ethnicity
Irina B. Grafova et al.
MEDICAL CARE RESEARCH AND REVIEW (2021)
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L. Yu et al.
CLINICAL CANCER RESEARCH (2021)
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Meredith S. Irwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
Frank Milton Balis et al.
PEDIATRIC BLOOD & CANCER (2020)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.
Keith Wheatley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Concordance of cancer registry and self-reported race, ethnicity, and cancer type: a report from the American Cancer Society's studies of cancer survivors
Tracy M. Layne et al.
CANCER CAUSES & CONTROL (2019)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
Kevin Campbell et al.
CANCER (2017)
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma
Christopher J. Forlenza et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study
Tara O. Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment and Outcomes of Patients With Relapsed, High-Risk Neuroblastoma: Results of German Trials
Thorsten Simon et al.
PEDIATRIC BLOOD & CANCER (2011)
Neuroblastoma: Biology, Prognosis, and Treatment
Julie R. Park et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Outcome in Children With Recurrent Neuroblastoma Treated With ABT-751 and Effect of ABT-751 on Proliferation of Neuroblastoma Cell Lines and on Tubulin Polymerization In Vitro
Holly J. Meany et al.
PEDIATRIC BLOOD & CANCER (2010)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
NKV Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
